INPLASY PROTOCOL

To cite: Xuan et al. A retrospective integrated analysis evaluate the effect and safety of Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy. Inplasy protocol 202230116. doi: 10.37766/inplasy2022.3.0116

Received: 22 March 2022
Published: 22 March 2022

Corresponding author:
Ying Han
hanying1@fmmu.edu.cn

Author Affiliation:
Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, 127 Changle West Road, Xi'an 710032, China.&National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Xijing Hospital, Air Force Military Medical University, Xi'an, Shaanxi, China.

Support: #81820108005, #81770569.

Review Stage at time of this submission: The review has not yet started.

Conflicts of interest: None declared.

INTRODUCTION

Review question / Objective: The efficacy and safety of UDCA combined with fenofibrate in the treatment of PBC patients with poor response to UDCA were evaluated by meta-analysis, so as to provide relevant suggestions for the clinical treatment of PBC.
**Condition being studied:** Primary biliary cholangitis (PBC), also known as primary biliary cirrhosis, is a chronic intrahepatic cholestatic disease, which is mainly characterized by progressive non supplicative inflammatory reaction of intrahepatic bile duct, and can develop into hepatic fibrosis and cirrhosis.

**METHODS**

**Search strategy:** For literature on ursodeoxycholic acid combined with fenofibrate in the treatment of adverse PBC published before December 20th, 2021, search databases will include Google Scholar, EMBASE, Web of Science, PubMed, the CNKI, VIP, Wanfang, and Cochrane Library.to identify systematic reviews or metaanalyses. The following search terms and their derivatives were used in multiple combinations: “Primary Biliary Cirrhosis”, “Ursodeoxycholic Acid”, “Fenofibrate”, “原发性胆汁性胆管炎”, “非诺贝特”, “熊去氧胆酸”.

**Participant or population:** PBC diagnosis meets any two of the following: 1 There is a biochemical basis for cholestasis. 2. Anti mitochondrial antibody was positive. 3. Histologically consistent with the diagnosis. And all patients did not use other liver disease treatment drugs,. Or other liver diseases.

**Intervention:** UDCA combined with fenofibrate.

**Comparator:** UDCA monotherapy.

**Study designs to be included:** RCT.

**Eligibility criteria:** 1) A randomized controlled trial or clinical controlled trial comparing UDCA alone with UDCA combined with fenofibrate.2) PBC diagnosis meets any two of the following: 1 There is a biochemical basis for cholestasis. 2. Anti mitochondrial antibody was positive. 3. Histologically consistent with the diagnosis.3) All patients did not use other liver disease treatment drugs.4) The research report shall include at least one of the indexes to evaluate the curative effect, such as biochemical and / or immunological indexes, survival rate, etc.5) For the research results of the same team, the results with the most cases and the most complete data are taken.

**Information sources:** For literature on mindfulness practice for adolescent emotional disorders published before December 20th, 2021, search databases will include Google Scholar, EMBASE, PubMed, the CNKI, the Chinese Science and Technology Periodical Database, VIP, Wanfang, and Cochrane Library.

**Main outcome(s):** The changes of biochemical levels such as ALP, alt, AST, GGT, TG IgM and the occurrence of major adverse events such as pruritus were included.

**Quality assessment / Risk of bias analysis:** The quality of the included meta-analysis and systematic evaluation was assessed by using the Cochrane systematic evaluation tool. Two researchers will assess the quality of the study and any differences will be resolved by the third author.

**Strategy of data synthesis:** Use revman5 4 conduct meta-analysis. For the binary counting data, the or value and 95% confidence interval (95% CI) of each literature were calculated. For continuous variable data, mean difference (MD) and 95% CI were used. We mainly use q test and I2 test to test heterogeneity. When p value < 0.10 or I2 value > 50% is considered to have significant heterogeneity, we use random effect model analysis. The fixed effect model was used when p value > 0.10 and I2 value < 50%. Subgroup and sensitivity analysis were used when necessary. Funnel plot was made to evaluate publication bias.
**Sensitivity analysis:** Sensitivity analysis will be performed by excluding tests one by one and observing whether there is a significant change in the synthesis results. If $I^2 \geq 50\%$ for the primary outcome, further analysis will be performed of each risk factor. The sensitivity of the article was analyzed by the change of effect quantity after deleting one report.

**Language:** English.

**Country(ies) involved:** China.

**Keywords:** primary biliary cholangitis, randomized controlled trial, fenofibrate, odds ratio, combination therapy, monotherapy, meta-analysis.

**Contributions of each author:**
Author 1 - Guoyun Xuan.
Author 2 - Ning liu.
Author 3 - Dawei Ding.
Author 4 - Ang Xu.
Author 5 - Yinan Hu.
Author 6 - Guanya Guo.
Author 7 - Xi Chen.
Author 8 - Yulong Shang.
Author 9 - Ying Han.